159 related articles for article (PubMed ID: 31915914)
1. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.
Choi SY; Chi BH; Lim B; Kyung YS; You D; Jeong IG; Song C; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2020 Feb; 146(2):537-543. PubMed ID: 31915914
[TBL] [Abstract][Full Text] [Related]
2. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Bhindi B; Karnes RJ; Rangel LJ; Mason RJ; Gettman MT; Frank I; Tollefson MK; Lin DW; Thompson RH; Boorjian SA
J Urol; 2017 Dec; 198(6):1286-1294. PubMed ID: 28669765
[TBL] [Abstract][Full Text] [Related]
3. Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?
Billis A; Meirelles LL; Freitas LL; Magna LA; Reis LO; Ferreira U
Int Urol Nephrol; 2011 Sep; 43(3):707-14. PubMed ID: 21336958
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
5. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
[TBL] [Abstract][Full Text] [Related]
6. Modification of the pT2 substage classification in prostate adenocarcinoma.
Ettel M; Kong M; Lee P; Zhou M; Melamed J; Deng FM
Hum Pathol; 2016 Oct; 56():57-63. PubMed ID: 27251951
[TBL] [Abstract][Full Text] [Related]
7. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
Antunes HP; Parada B; Carvalho J; Eliseu M; Jarimba R; Oliveira R; Tavares-da-Silva E; Figueiredo A
Arch Ital Urol Androl; 2018 Sep; 90(3):191-194. PubMed ID: 30362685
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
10. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
[TBL] [Abstract][Full Text] [Related]
13. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
14. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
15. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
16. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
17. High percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage T3a prostate cancer with a negative surgical margin.
You D; Jeong IG; Song C; Cho YM; Hong JH; Kim CS; Ahn H
Int J Urol; 2014 May; 21(5):484-9. PubMed ID: 24256352
[TBL] [Abstract][Full Text] [Related]
18. In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.
Ito Y; Vertosick EA; Sjoberg DD; Vickers AJ; Al-Ahmadie HA; Chen YB; Gopalan A; Sirintrapun SJ; Tickoo SK; Eastham JA; Scardino PT; Reuter VE; Fine SW
Am J Surg Pathol; 2019 Aug; 43(8):1061-1065. PubMed ID: 31107718
[TBL] [Abstract][Full Text] [Related]
19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
20. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
